Emil Poulsen, MSc, serves as Director, Drug Substance Development, CMC at Hemab and has more than 20 years of experience in the biotechnology industry across early- and late-stage process development. With experience in monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and fusion proteins, he has successfully seen programs through Process Performance Qualification, submission and approval by EMA and FDA. Prior to joining Hemab, he worked at Biogen, Zymenex, CMC Biologics, Novozymes, Alpharma and was most recently an Associate Director of CMC Late-Stage Development Manufacturing at Genmab. He earned a Master of Science in Chemical Engineering and Biotechnology from the Technical University of Denmark.